Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

January 3, 2024

https://www.globenewswire.com/news-release/2024/01/03/2803646/0/en/Vigil-Neuroscience-Provides-2023-Year-in-Review-and-Highlights-Upcoming-2024-Milestones.html

– On track to report interim Phase 1 data for VG-3927 in healthy volunteers in mid-2024 and Phase 2 results from IGNITE clinical trial evaluating iluzanebart in ALSP in Q3 2024 –

Read more at globenewswire.com

Related news for (VIGL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.